Invesaro

Stocks Comparison

Immucell vs Lantheus: revenue, profit, margins and growth compared

Immucell brought in $27.6M of revenue in fiscal 2025, Lantheus $1.5B in fiscal 2025. Revenue changed by +4.3% at Immucell and +0.5% at Lantheus on the year before, so Immucell grew faster. Immucell kept -3.8% of its revenue as net profit, Lantheus 15.2%. Free cash flow was $1.2M at Immucell and $354.1M at Lantheus.

Side by side, latest fiscal year

ICCCLNTH
Fiscal year endedFY2025 (December 31, 2025)FY2025 (December 31, 2025)
Revenue$27.6M$1.5B
Revenue growth+4.3%+0.5%
Net income-$1M$233.6M
Net margin-3.8%15.2%
Free cash flow$1.2M$354.1M
Free cash flow margin4.4%23.0%
Earnings per share (diluted)-$0.12$3.41
Cash$3.8M$359.1M
Debt$9.1M$738K
Price to earningsn/a29.3
Market value$90.1M$6.5B
Dividend yieldn/an/a
Rank by revenue in sector#396 of 523 · Health care#118 of 523 · Health care

Over the years

Revenue
ICCC FY2018: $11MICCC FY2019: $13.7MICCC FY2020: $15.3MICCC FY2021: $19.2MICCC FY2022: $18.6MICCC FY2023: $17.5MICCC FY2024: $26.5MICCC FY2025: $27.6MLNTH FY2018: $343.4MLNTH FY2019: $347.3MLNTH FY2020: $339.4MLNTH FY2021: $425.2MLNTH FY2022: $935.1MLNTH FY2023: $1.3BLNTH FY2024: $1.5BLNTH FY2025: $1.5BFY18FY19FY20FY21FY22FY23FY24FY25
ICCC $27.6MLNTH $1.5B
Net income
ICCC FY2018: -$2.3MICCC FY2019: -$1.3MICCC FY2020: -$1MICCC FY2021: -$78.3KICCC FY2022: -$2.5MICCC FY2023: -$5.8MICCC FY2024: -$2.2MICCC FY2025: -$1MLNTH FY2018: $40.5MLNTH FY2019: $31.7MLNTH FY2020: -$13.5MLNTH FY2021: -$71.3MLNTH FY2022: $28.1MLNTH FY2023: $326.7MLNTH FY2024: $312.4MLNTH FY2025: $233.6MFY18FY19FY20FY21FY22FY23FY24FY25
ICCC -$1MLNTH $233.6M
Net margin
ICCC FY2018: -21.1%ICCC FY2019: -9.4%ICCC FY2020: -6.7%ICCC FY2021: -0.4%ICCC FY2022: -13.4%ICCC FY2023: -33.1%ICCC FY2024: -8.1%ICCC FY2025: -3.8%LNTH FY2018: 11.8%LNTH FY2019: 9.1%LNTH FY2020: -4.0%LNTH FY2021: -16.8%LNTH FY2022: 3.0%LNTH FY2023: 25.2%LNTH FY2024: 20.4%LNTH FY2025: 15.2%FY18FY19FY20FY21FY22FY23FY24FY25
ICCC -3.8%LNTH 15.2%
Revenue growth
ICCC FY2019: +24.9%ICCC FY2020: +11.8%ICCC FY2021: +25.4%ICCC FY2022: -3.5%ICCC FY2023: -5.9%ICCC FY2024: +51.6%ICCC FY2025: +4.3%LNTH FY2019: +1.2%LNTH FY2020: -2.3%LNTH FY2021: +25.3%LNTH FY2022: +119.9%LNTH FY2023: +38.6%LNTH FY2024: +18.3%LNTH FY2025: +0.5%FY19FY20FY21FY22FY23FY24FY25
ICCC +4.3%LNTH +0.5%
Free cash flow
ICCC FY2018: -$2.4MICCC FY2019: -$1.2MICCC FY2020: -$2.8MICCC FY2021: -$1.7MICCC FY2022: -$5.5MICCC FY2023: -$6.6MICCC FY2024: -$107.8KICCC FY2025: $1.2MLNTH FY2018: $41.1MLNTH FY2019: $58.3MLNTH FY2020: $16.4MLNTH FY2021: $53.9MLNTH FY2022: $21.8MLNTH FY2023: $259.9MLNTH FY2024: $493.1MLNTH FY2025: $354.1MFY18FY19FY20FY21FY22FY23FY24FY25
ICCC $1.2MLNTH $354.1M

Fiscal years as each company reports them; the two may end in different months.

Questions about Immucell and Lantheus

Which is bigger by revenue, Immucell or Lantheus?

Lantheus is bigger by revenue: $1.5B in fiscal 2025, against $27.6M for Immucell in fiscal 2025.

Which keeps more of its revenue as profit, Immucell or Lantheus?

Immucell had a net margin of -3.8% in fiscal 2025; Lantheus had 15.2% in fiscal 2025.

Which grew revenue faster, Immucell or Lantheus?

In their latest fiscal years revenue changed by +4.3% at Immucell and +0.5% at Lantheus.

Where do these numbers come from?

From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.

More comparisons

Compare more companies